Clinical Trial Detail

NCT ID NCT01730833
Title Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors City of Hope Medical Center
Indications

breast cancer

Therapies

Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST